Major Queensland hospital to close pathology labs amid potential formaldehyde exposure investigation
Published . Updated .
Key takeaways
- About 400 staff affected by closure at both Mater’s Brisbane and Springfield hospitals, with financial sustainability of pathology business a factor Get our breaking news email , free app or daily news podcast In-house pathology services at one of Queensland’s biggest hospitals will permanently close amid an investigation into potential formaldehyde exposure and continual financial strain.
- Exposed: XLV, XBI, LLY, JNJ, PFE
- Market reaction: price tracking starts with the next trading session.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
About 400 staff affected by closure at both Mater’s Brisbane and Springfield hospitals, with financial sustainability of pathology business a factor Get our breaking news email , free app or daily news podcast In-house pathology services at one of Queensland’s biggest hospitals will permanently close amid an investigation into potential formaldehyde exposure and continual financial strain. The closure, which affects 400 staff across Mater’s Brisbane and Springfield hospitals, includes the lab which handles foetus and newborn tissue and cell testing for unexpected deaths. Continue reading...
Directly affected
- No company is named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “hospital” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “hospital” (pharma and health) in this story.
- LLY Eli Lilly and+21.6% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “hospital” (pharma and health) in this story.
- JNJ Johnson & Johnson+1.5% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “hospital” (pharma and health) in this story.
- PFE Pfizer+8.9% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “hospital” (pharma and health) in this story.
- MRK Merck+4.0% 17d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “hospital” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLV | -2.95% | -0.31% | base | after close | after close | after close | after close |
| XBI | +1.84% | +3.78% | base | after close | after close | after close | after close |
| LLY | -9.22% | -2.71% | base | after close | after close | after close | after close |
| JNJ | -0.68% | +1.70% | base | after close | after close | after close | after close |
| PFE | -3.00% | -2.47% | base | after close | after close | after close | after close |
| MRK | -4.45% | -1.43% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
About 400 staff affected by closure at both Mater’s Brisbane and Springfield hospitals, with financial sustainability of pathology business a factor Get our breaking news email , free app or daily news podcast In-house pathology services a…
Source: The Guardian
Select Sector Spdr Tr (XLV) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| Johnson & Johnson (JNJ) | three days earlier | +1.70% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -0.68% | final price |
| Eli Lilly (LLY) | three days earlier | -2.71% | final price |
| Eli Lilly (LLY) | five days earlier | -9.22% | final price |
| Merck (MRK) | three days earlier | -1.43% | final price |
| Merck (MRK) | five days earlier | -4.45% | final price |
| Pfizer (PFE) | three days earlier | -2.47% | final price |
| Pfizer (PFE) | five days earlier | -3.00% | final price |
| Spdr Series Trust (XBI) | three days earlier | +3.78% | final price |
| Spdr Series Trust (XBI) | five days earlier | +1.84% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | -0.31% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -2.95% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 34 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 56 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 74 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 76 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies mentioned with this story
- XLV Select Sector Spdr Tr
In “Major Queensland hospital to close pathology labs amid potential formaldehyde exposure investigation,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “hospital” (pharma and health) in this story
- XBI Spdr Series Trust
For “Major Queensland hospital to close pathology labs amid potential formaldehyde exposure investigation,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “hospital” (pharma and health) in this story
- LLY Eli Lilly
In “Major Queensland hospital to close pathology labs amid potential formaldehyde exposure investigation,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “hospital” (pharma and health) in this story
- JNJ Johnson & Johnson
For “Major Queensland hospital to close pathology labs amid potential formaldehyde exposure investigation,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “hospital” (pharma and health) in this story
- PFE Pfizer
For “Major Queensland hospital to close pathology labs amid potential formaldehyde exposure investigation,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “hospital” (pharma and health) in this story
- MRK Merck
Merck (MRK) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “Major Queensland hospital to close pathology labs amid potential formaldehyde exposure investigation.” Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “hospital” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
“Major Queensland hospital to close pathology labs amid potential formaldehyde exposure investigation” (3 Nov 2026) reaches Select Sector Spdr Tr (XLV) through this story.
The link for Select Sector Spdr Tr (XLV) is this: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “hospital” (pharma and health) in this story
Also listed, Spdr Series Trust (XBI): SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “hospital” (pharma and health) in this story
Dates and price levels for Select Sector Spdr Tr (XLV)
LLY traded between 1131.55 and 1447.86 across 20 sessions. The latest close on file is 1415.62.
A simple score for Select Sector Spdr Tr (XLV)
46 out of 100
“Major Queensland hospital to close pathology labs amid potential formaldehyde exposure investigation” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.